Transition to KPL-387 Monotherapy Dosing & Administration Study
← catalyst calendarNCT07288216 · readout in 499 d
Sponsored by Kiniksa Pharmaceuticals International, plc (industry) · KNSA — their whole pipeline →. With Kiniksa Pharmaceuticals, GmbH.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
80estimated
Sites
41
Countries
Canada, France, Germany +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-25 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Recurrent Pericarditis
- Heart Diseases
- Pericarditis
Intervention
- Drug: KPL-387
Primary outcomes
what the primary-completion date above is the date OFPosology: Proportion of participants free from Pericarditis Recurrence by Week 16
measured From first administration of study drug up to Week 16
Long-Term Extension: Annualized rate of Pericarditis Recurrence through the end of the LTE.
measured Up to 24 Months
Permalink · KNSA's whole pipeline · Catalyst calendar · Every registered study · What changed